|
Objective: Irritable bowel syndrome (irritable bowel syndrome, IBS), abdominal discomfort or abdominal pain accompanied by abnormal bowel movements mainly a group of intestinal dysfunction syndrome, the lack of obvious morphological and biochemical abnormalities change. Can be divided according to the stool constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), mixed (IBS-M) and Uncertain pathogenic factors and the exact pathogenesis is not yet fully elucidated. The nerve - immune - endocrine Network disorders is a more comprehensive understanding of IBS. The IBS pathophysiology main for gastrointestinal motility disorders, visceral hypersensitivity disorders and neuroendocrine regulation. Gastrointestinal hormones, not only as to the peptidergic neurotransmitters play a role, but also nerves - immunomodulatory mechanisms involved in the pathogenesis of IBS. The gastrointestinal hormone can be divided into two major categories of excitatory and inhibitory, excitatory neurotransmitter serotonin (5-HT), acetylcholine (Ach), P substance (SP), and so on; inhibitory neurotransmitter nitric oxide (NO ), vasoactive intestinal peptide (VIP), calcitonin gene-related peptide (CGRP), these hormones in the gastrointestinal tract and the brain changes affect nerve - immune - endocrine regulation of the network, so that the brain-gut axis disorder, which can lead to a series of changes, such as abnormal gastrointestinal motility, visceral sensitivity changes. IBS vest TCM \in the intestine. The experimental drug has the aromatic Huazhuo, qi pain the stomach Daozhi efficacy, clinically proven its good treatment of gastrointestinal functional disorders, enteritis, dysentery, diarrhea, abdominal pain. To investigate the experimental drug in the treatment of IBS-D abnormal gastrointestinal motility and visceral sensation regulation mechanism, In this experiment, the rats of the BS-D model, the observed experimental medication on the expression levels of the colonic mucosa mast cells and related gastrointestinal hormone changes. Method: 1. Establish a rat model of IBS-D; 2. Rats weight change, diarrhea, calculate the rate of weight change, diarrhea index; 3. Detection hematocrit (HCT), serum electrolytes; 4. Nitrate reductase Law the the serum NO fluorescence method serum level of 5-HT; 5. radioimmunoassay detection of colon tissue VIP, SP content; 6. experimental colon tissue morphology by light microscopy and intestinal mucosal mast cells (MC) change; Results: 1.IBS-D rats obviously persistent diarrhea symptoms, weight downward trend, colon tissue morphology visible mucosal epithelial arrangement than the rule, and no significant hyperemia, edema, ulcers and erosions histopathological changes . Experimental medication can significantly reduce the IBS-D rats diarrhea index (P LT; 0.05), slowing weight loss. The experimental drug has a clear role in antidiarrheal, correctable IBS-D rat blood electrolyte imbalance, improve hematocrit. The experimental drug is high, the middle dose group IBS-D can be effectively raised serum NO ,5-HT levels (P lt; 0.01), to improve gastrointestinal motility disorders. 5 experimental medication, the middle dose group intentionally cut IBS-D the rat colon organizations VIP expression (P lt; 0.05), to participate in the water metabolism regulation. 6. Experimental medication, the middle dose group significantly inhibited the colonic mucosa MC number (P lt; 0.01) and the expression of SP (P lt; 0.05), involved in the regulation of visceral sensory abnormalities. Conclusion: The high lactose feed joint restraint stress-established rat model of IBS-D, with a high incidence of repeatability, can simulate the characteristics of human IBS-D ideal of diarrhea-predominant irritable bowel syndrome model . The experimental medication have clear the antidiarrheal efficacy, and its role in the treatment of IBS-D by regulating neurotransmitter release, and inhibiting the abnormal proliferation of MC, multi-target involved in the regulation of gastrointestinal motility and visceral sensation exception, the combined effects of the multi-level achieved. The experimental medication experimental IBS-D has a dose-dependent effect.
|